CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Danger Zone: Mondelez International (MDLZ).
Stop us if you’ve heard this story before: slowing organic revenue growth, questionable non-GAAP metrics, and a large investment by activist Bill Ackman. No, we’re not talking about Valeant Pharmaceuticals (VRX), which is down 53% since we put it in the Danger Zone in late February. This time, we’re talking about Mondelez International (MDLZ).
Photo Credit: (Flickr)